Synonyms: TNFRSF4, CD134
Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | OX1 receptor | OX2 receptor |
|---|---|---|---|
| EMPA | 2 | ||
| Almorexant HCl | 7 | ||
| SB408124 | 1 | ||
| SB-334867 | 5 |
| Description |
Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD.
|
References |
|---|
| CAS No. | 2244739-29-3 |
|---|---|
| Molecular Weight | 145.94 |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT04198766 | RECRUITING | Drug: INBRX-106 - Hexavalent OX40 agonist antibody|Drug: pem | Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer | Inhibrx Biosciences, Inc | 2019-12-10 | PHASE1; PHASE2 |
| NCT06353997 | RECRUITING | Drug: Pembrolizumab|Drug: INBRX-106 | Triple Negative Breast Cancer | Providence Health & Services | 2024-09-05 | PHASE2 |
| NCT03971409 | ACTIVE_NOT_RECRUITING | Drug: Avelumab|Drug: Binimetinib|Drug: Liposomal Doxorubicin | Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma; Unresectable Breast Carcinoma | Laura Huppert, MD, BA | 2019-07-08 | PHASE2 |
| NCT07461181 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Solid Tumors | Ruijin Hospital | 2024-12-30 | PHASE1; PHASE2 | |
| NCT03092856 | ACTIVE_NOT_RECRUITING | Drug: Axitinib | Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Cancer; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer | University of Southern California | 2017-07-19 | PHASE2 |
| NCT04714983 | SUSPENDED | Liver Metastases; Liver Metastasis Colon Cancer; Colorectal Cancer; Breast Cancer; Gastric Cancer; Periampullary Cancer; Melanoma; Renal Cell Cancer; Sarcoma; Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors | DNAtrix, Inc. | 2021-02-15 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-29)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.